Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Equity (2018 - 2025)

VYNE Therapeutics' Return on Equity history spans 8 years, with the latest figure at 0.0% for Q4 2025.

  • For Q4 2025, Return on Equity changed 0.0% year-over-year to 0.0%; the TTM value through Dec 2025 reached 0.0%, changed 0.0%, while the annual FY2025 figure was 0.01%, 1.0% up from the prior year.
  • Return on Equity reached 0.0% in Q4 2025 per VYNE's latest filing, down from 0.0% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.3% in Q4 2022 to a low of 3.45% in Q1 2021.
  • Average Return on Equity over 5 years is 0.29%, with a median of 0.01% recorded in 2024.
  • The largest YoY upside for Return on Equity was 533bps in 2021 against a maximum downside of -69bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 0.54% in 2021, then surged by 156bps to 0.3% in 2022, then crashed by -104bps to 0.01% in 2023, then skyrocketed by 96bps to 0.0% in 2024, then crashed by -54bps to 0.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Return on Equity are 0.0% (Q4 2025), 0.0% (Q2 2025), and 0.0% (Q1 2025).